Volume 11,Issue 3
Observation on the Effect of Pharmaceutical Intervention on Standardizing the Use of Risperidone Among Grassroots Patients
Objective: To explore the impact of pharmaceutical intervention on grassroots patients taking risperidone medication on their standardized medication, treatment effects and medication safety. Methods: 80 grassroots patients admitted to our hospital from January 2025 to December 2025 who required risperidone treatment were selected as the research subjects and divided into two groups with 40 cases in each group using the random number table method. The control group received routine medication guidance, while the observation group received systematic pharmaceutical intervention based on the control group. Results: The standard medication rate and total effective rate of treatment in the observation group were higher than those in the control group, and the incidence of adverse drug reactions was lower than that in the control group (P<0.05). Conclusion: Pharmaceutical intervention for grassroots patients taking risperidone can effectively improve patients’ standard medication levels, enhance clinical treatment effects, and reduce the occurrence of adverse drug reactions, which has grassroots clinical promotion value.
[1] Zheng CJ, Chen Z, Shen XD, et al., 2025, Analysis of 4 Cases of Clinical Pharmacists Providing Pharmaceutical Services in the Pediatric Psychiatry Department. Clinical Rational Drug Use, 18(1): 155–158.
[2] Zhang Q, Yun Y, He L, 2024, Pharmaceutical Care of a Patient With Hyperprolactinemia Caused by Risperidone. Chinese Pharmacovigilance, 21(8): 936–938 + 942.
[3] Yang O, 2024, Analysis of the Pharmaceutical Effects of Risperidone and Aripiprazole in the Treatment of Schizophrenia. Heilongjiang Traditional Chinese Medicine, 53(1): 70–72.
[4] Liu K, Liang J, Nie LJ, et al., 2024, Study on the Correlation Between Risperidone Plasma Concentration and Thyroid Function. Journal of Bengbu Medical College, 49(2): 244–248 + 252.
[5] Zheng N, Jia F, Zhu DW, 2023, Markov Evaluation of Paliperidone Palmitate and Risperidone in the Treatment of Schizophrenia. Journal of Clinical Drug Therapy, 21(10): 17–22.
[6] Huang WC, Huang SY, Chen JL, et al., 2023, Uncertainty of Simultaneous Determination of Risperidone and Paliperidone in Human Serum by LC-MS/MS. Today’s Pharmacy, 33(4): 295–300.
[7] Xu Q, Pan FE, Peng S, 2021, Effect of Pharmaceutical Intervention Based on Timing Theory on Glucose and Lipid Metabolism in Patients With Schizophrenia Treated With Risperidone. Journal of Psychiatry, 34(6): 539–542.
